|
US3707475A
(en)
|
1970-11-16 |
1972-12-26 |
Pfizer |
Antiinflammatory imidazoles
|
|
DE3029376A1
(de)
|
1980-07-31 |
1982-03-18 |
Nepera Chemical Co. Inc., Harriman, N.Y. |
Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
|
|
EP0149884B1
(en)
|
1983-09-09 |
1992-12-16 |
Takeda Chemical Industries, Ltd. |
5-pyridyl-1,3-thiazole derivatives, their production and use
|
|
JP2722586B2
(ja)
|
1989-01-13 |
1998-03-04 |
大正製薬株式会社 |
インドリルイミダゾール誘導体
|
|
JP2808460B2
(ja)
|
1989-11-16 |
1998-10-08 |
大正製薬株式会社 |
イミダゾール誘導体
|
|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
|
US5717100A
(en)
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
|
GB2306108A
(en)
|
1995-10-13 |
1997-04-30 |
Merck & Co Inc |
Treatment of Raf-mediated cancers with imidazole derivatives
|
|
WO1998008845A1
(en)
|
1996-08-27 |
1998-03-05 |
Novartis Ag |
Herbicidal s-substituted 1,2,4,6-thiatriazines
|
|
EP1014953B1
(en)
|
1997-03-05 |
2012-04-25 |
Sugen, Inc. |
Formulations for hydrophobic pharmaceutical agents
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
GB9711650D0
(en)
|
1997-06-05 |
1997-07-30 |
Pfizer Ltd |
Compounds useful in therapy
|
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
|
AU4798000A
(en)
|
1999-04-09 |
2000-11-14 |
Smithkline Beecham Corporation |
Triarylimidazoles
|
|
CA2366932C
(en)
|
1999-04-15 |
2009-08-25 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
JP2000302680A
(ja)
|
1999-04-23 |
2000-10-31 |
Takeda Chem Ind Ltd |
脳保護剤
|
|
ES2270867T3
(es)
|
1999-09-23 |
2007-04-16 |
Astrazeneca Ab |
Compuestos de quinazolina terapeuticos.
|
|
CA2395564A1
(en)
|
1999-11-22 |
2001-05-31 |
Smithkline Beecham Plc |
Novel compounds
|
|
EP1251849A1
(en)
|
2000-01-18 |
2002-10-30 |
Vertex Pharmaceuticals Incorporated |
Gyrase inhibitors and uses thereof
|
|
MXPA02007134A
(es)
|
2000-01-18 |
2003-03-27 |
Vertex Pharma |
Inhibidores de girasa y usos de los mismos.
|
|
AR029803A1
(es)
|
2000-02-21 |
2003-07-16 |
Smithkline Beecham Plc |
Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
|
|
GB0005357D0
(en)
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
|
EP1263753B1
(en)
|
2000-03-06 |
2004-05-06 |
SmithKline Beecham plc |
Imidazol derivatives as raf kinase inhibitors
|
|
GB0007405D0
(en)
|
2000-03-27 |
2000-05-17 |
Smithkline Beecham Corp |
Compounds
|
|
CA2404384A1
(en)
|
2000-03-30 |
2001-10-11 |
Takeda Chemical Industries, Ltd. |
Substituted 1,3-thiazole compounds, their production and use
|
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
|
WO2001096308A1
(en)
|
2000-06-12 |
2001-12-20 |
Eisai Co., Ltd. |
1,2-dihydropyridine compounds, process for preparation of the same and use thereof
|
|
AU7349801A
(en)
|
2000-07-19 |
2002-01-30 |
Warner Lambert Co |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
EP1332131A2
(en)
|
2000-11-07 |
2003-08-06 |
Bristol-Myers Squibb Company |
Acid derivatives useful as serine protease inhibitors
|
|
ES2289004T3
(es)
|
2000-11-20 |
2008-02-01 |
Smithkline Beecham Corporation |
Nuevos compuestos.
|
|
US7238813B2
(en)
|
2000-11-29 |
2007-07-03 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
AU2002241966A1
(en)
|
2001-01-26 |
2002-08-28 |
Chugai Seiyaku Kabushiki Kaisha |
Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
|
|
WO2002062792A1
(en)
|
2001-02-02 |
2002-08-15 |
Takeda Chemical Industries, Ltd. |
Jnk inhibitor
|
|
US20030009034A1
(en)
|
2001-03-22 |
2003-01-09 |
Neil Wishart |
Transition metal mediated process
|
|
JP2002338537A
(ja)
|
2001-05-16 |
2002-11-27 |
Mitsubishi Pharma Corp |
アミド化合物およびその医薬用途
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
GB0129260D0
(en)
|
2001-12-06 |
2002-01-23 |
Eisai London Res Lab Ltd |
Pharmaceutical compositions and their uses
|
|
US8299108B2
(en)
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
MXPA04009541A
(es)
|
2002-03-29 |
2005-01-25 |
Chiron Corp |
Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
|
|
AR039241A1
(es)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
|
MXPA05002332A
(es)
|
2002-09-18 |
2005-06-08 |
Pfizer Prod Inc |
Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
|
|
CN1681805A
(zh)
|
2002-09-18 |
2005-10-12 |
辉瑞产品公司 |
作为转化生长因子(tgf)抑制剂的新的咪唑类化合物
|
|
US7531553B2
(en)
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
PE20050952A1
(es)
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
|
WO2005034869A2
(en)
|
2003-10-08 |
2005-04-21 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
EP1682126B1
(en)
|
2003-10-16 |
2009-07-01 |
Novartis Vaccines and Diagnostics, Inc. |
Substituted benzazoles and use thereof as inhibitors of raf kinase
|
|
AU2004289539C1
(en)
|
2003-11-14 |
2012-06-07 |
Lorus Therapeutics Inc. |
Aryl imidazoles and their use as anti-cancer agents
|
|
NZ549003A
(en)
|
2004-03-05 |
2009-07-31 |
Taisho Pharmaceutical Co Ltd |
Thiazole derivative as an ALK5 inhibitor
|
|
KR100749566B1
(ko)
|
2004-04-21 |
2007-08-16 |
이화여자대학교 산학협력단 |
Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
|
|
US20060106020A1
(en)
|
2004-04-28 |
2006-05-18 |
Rodgers James D |
Tetracyclic inhibitors of Janus kinases
|
|
PE20060315A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de tiazol como moduladores de ppar
|
|
KR100883289B1
(ko)
|
2004-06-11 |
2009-02-11 |
니뽄 다바코 산교 가부시키가이샤 |
암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
|
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
|
GB0415367D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JP2008511631A
(ja)
|
2004-08-31 |
2008-04-17 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール
|
|
WO2006038734A1
(en)
|
2004-10-08 |
2006-04-13 |
Astellas Pharma Inc. |
Pyridazinone derivatives cytokines inhibitors
|
|
AU2005295734A1
(en)
|
2004-10-15 |
2006-04-27 |
Biogen Idec Ma Inc. |
Methods of treating vascular injuries
|
|
JP2007246520A
(ja)
|
2006-02-15 |
2007-09-27 |
Takeda Yuichiro |
Ｒａｇｅ阻害剤
|
|
EP2007393B1
(en)
|
2006-04-07 |
2013-08-21 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
|
|
AU2007282535B9
(en)
|
2006-08-08 |
2013-06-20 |
Chugai Seiyaku Kabushiki Kaisha |
Pyrimidine derivative as PI3K inhibitor and use thereof
|
|
WO2008071605A2
(en)
|
2006-12-15 |
2008-06-19 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
UA98961C2
(uk)
|
2007-06-27 |
2012-07-10 |
Астразенека Аб |
Похідні піразинону та їх застосування у лікуванні легеневих захворювань
|
|
CL2008001933A1
(es)
|
2007-06-29 |
2009-09-25 |
Millennium Pharm Inc |
Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
|
|
EP2167497A2
(en)
|
2007-06-29 |
2010-03-31 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclic compounds useful as raf kinase inhibitors
|
|
CA2692379A1
(en)
|
2007-07-02 |
2009-01-08 |
Boehringer Ingelheim International Gmbh |
Antiproliferative compounds based on 5-membered heterocycles
|
|
JP2010533159A
(ja)
|
2007-07-09 |
2010-10-21 |
アストラゼネカ アクチボラグ |
化合物９４７
|
|
JP2010533729A
(ja)
|
2007-07-17 |
2010-10-28 |
プレキシコン，インコーポレーテッド |
キナーゼ調節のための化合物と方法、及びそのための適応
|
|
BRPI0814441A2
(pt)
|
2007-07-19 |
2015-07-14 |
Schering Corp |
Compostos de amida heterocíclica como inibidores de proteína cinase
|
|
EP2197876A1
(en)
|
2007-08-29 |
2010-06-23 |
Glaxosmithkline LLC |
Thiazole and oxazole kinase inhibitors
|
|
UY31322A1
(es)
|
2007-09-05 |
2009-04-30 |
|
Amidas heterocíclicas y sus métodos de uso-975
|
|
WO2009047163A1
(en)
|
2007-10-10 |
2009-04-16 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
TW200940537A
(en)
|
2008-02-26 |
2009-10-01 |
Astrazeneca Ab |
Heterocyclic urea derivatives and methods of use thereof
|
|
US8865732B2
(en)
|
2008-03-21 |
2014-10-21 |
Novartis Ag |
Heterocyclic compounds and uses thereof
|
|
WO2009115572A2
(en)
|
2008-03-21 |
2009-09-24 |
Novartis Ag |
Novel heterocyclic compounds and uses therof
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
EA201001847A1
(ru)
|
2008-06-11 |
2011-08-30 |
Айрм Ллк |
Соединения и композиции, применяемые для лечения малярии
|
|
EP2324008B1
(en)
|
2008-07-24 |
2012-05-09 |
Nerviano Medical Sciences S.R.L. |
3,4-diarylpyrazoles as protein kinase inhibitors
|
|
AU2009284098B2
(en)
|
2008-08-22 |
2012-03-29 |
Astex Therapeutics Ltd. |
Pyrrolopyrimidine compounds as CDK inhibitors
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
PL3354650T3
(pl)
|
2008-12-19 |
2022-06-13 |
Vertex Pharmaceuticals Incorporated |
Związki przydatne jako inhibitory kinazy atr
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
AU2010291206A1
(en)
|
2009-09-04 |
2012-02-23 |
Novartis Ag |
Bipyridines useful for the treatment of proliferative diseases
|
|
EP2498608A4
(en)
|
2009-11-10 |
2013-04-24 |
Glaxosmithkline Llc |
BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
|
|
US9315491B2
(en)
|
2009-12-28 |
2016-04-19 |
Development Center For Biotechnology |
Pyrimidine compounds as mTOR and PI3K inhibitors
|
|
JP5794922B2
(ja)
|
2009-12-28 |
2015-10-14 |
一般社団法人ファルマバレープロジェクト支援機構 |
１，３，４−オキサジアゾール−２−カルボキサミド化合物
|
|
KR20110123657A
(ko)
|
2010-05-07 |
2011-11-15 |
에스케이케미칼주식회사 |
피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
|
|
BR112012032884A2
(pt)
|
2010-06-25 |
2016-11-08 |
Novartis Ag |
compostos e composições heteroarílicos como inibidores de quinase proteica
|
|
JP5903433B2
(ja)
|
2010-08-26 |
2016-04-13 |
ノバルティス アーゲー |
癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ
|
|
CN101993415B
(zh)
|
2010-09-15 |
2013-08-14 |
北京韩美药品有限公司 |
作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
|
|
AR083797A1
(es)
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
|
PE20141360A1
(es)
|
2011-02-07 |
2014-10-13 |
Plexxikon Inc |
Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
|
|
EP2739143B1
(en)
|
2011-08-05 |
2018-07-11 |
Gary A. Flynn |
Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
|
|
US8569283B2
(en)
|
2011-09-01 |
2013-10-29 |
Valentina Molteni |
Compounds and compositions as c-Kit kinase inhibitors
|
|
BR112014006743A8
(pt)
|
2011-09-21 |
2018-01-09 |
Cellzome Ltd |
composto, uso de um composto, e, método para tratar, controlar, retardar ou impedir uma ou mais condições
|
|
EP2844655A1
(en)
|
2012-05-02 |
2015-03-11 |
Lupin Limited |
Substituted pyridine compounds as crac modulators
|
|
WO2013171640A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
|
AR091654A1
(es)
|
2012-07-02 |
2015-02-18 |
Biogen Idec Inc |
COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
IN2015DN00450A
(enExample)
*
|
2012-08-07 |
2015-06-26 |
Novartis Ag |
|
|
CN104582706A
(zh)
|
2012-09-04 |
2015-04-29 |
葛兰素史克有限责任公司 |
辅助癌症治疗的方法
|
|
JP6535430B2
(ja)
|
2012-09-28 |
2019-06-26 |
イグニタ、インク． |
非定型プロテインキナーゼｃのアザキナゾリン阻害薬
|
|
WO2014058691A1
(en)
|
2012-10-08 |
2014-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
EP2934515B1
(en)
*
|
2012-12-20 |
2018-04-04 |
Novartis AG |
A pharmaceutical combination comprising binimetinib
|
|
US9242969B2
(en)
*
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
US9913844B2
(en)
*
|
2013-03-21 |
2018-03-13 |
Novartis Ag |
Combination therapy
|
|
DK3063143T3
(en)
*
|
2013-11-01 |
2018-08-20 |
Novartis Ag |
Amino heteroaryl benzamides as kinase inhibitors
|
|
BR112016014481B1
(pt)
*
|
2013-12-20 |
2022-11-08 |
Biomed Valley Discoveries, Inc |
Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
|
|
ES2844211T3
(es)
|
2014-09-12 |
2021-07-21 |
Novartis Ag |
Compuestos y composiciones en calidad de inhibidores de quinasa
|
|
UY36294A
(es)
*
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
JP6636014B2
(ja)
|
2014-09-12 |
2020-01-29 |
ノバルティス アーゲー |
Ｒａｆキナーゼ阻害剤としての化合物および組成物
|
|
WO2016115376A1
(en)
*
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Of California |
Detection and treatment of double drug resistant melanomas
|
|
CA2991805A1
(en)
|
2015-07-10 |
2017-01-19 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
|
WO2017037587A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
Combination of ribociclib and dabrafenib for treating or preventing cancer
|
|
WO2017037575A1
(en)
*
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
|
|
BR112018074941A2
(pt)
*
|
2016-06-03 |
2019-03-12 |
Caponigro Giordano |
combinações farmacêuticas
|
|
BR112018075371A2
(pt)
*
|
2016-06-10 |
2019-03-19 |
Novartis Ag |
usos terapêuticos de um inibidor de c-raf
|
|
CN109715163B
(zh)
*
|
2016-09-19 |
2022-11-22 |
诺华股份有限公司 |
包含raf抑制剂和erk抑制剂的治疗组合
|
|
US11590133B2
(en)
|
2016-12-11 |
2023-02-28 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for treatment of BRAF mutant cancers
|
|
WO2018203219A1
(en)
|
2017-05-02 |
2018-11-08 |
Novartis Ag |
Combination therapy
|
|
WO2018213302A1
(en)
|
2017-05-16 |
2018-11-22 |
Biomed Valley Discoveries, Inc. |
Compositions and methods for treating cancer with atypical braf mutations
|
|
TW202023556A
(zh)
|
2018-08-27 |
2020-07-01 |
美商庫拉腫瘤技術股份有限公司 |
以mapk路徑抑制劑治療腺癌
|
|
CA3123510A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer
|
|
EP4563150A3
(en)
|
2019-05-13 |
2025-07-23 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
|
|
TW202140029A
(zh)
|
2020-02-18 |
2021-11-01 |
瑞士商諾華公司 |
用於治療ｂｒａｆ突變型ｎｓｃｌｃ的包含ｒａｆ抑制劑之治療組合
|
|
WO2021229439A1
(en)
|
2020-05-12 |
2021-11-18 |
Novartis Ag |
Therapeutic combinations comprising a craf inhibitor
|